What Researchers Did
Researchers investigated the long-term efficacy of alternobaric oxygen therapy (ABOT) in 20 patients with unilateral Ménière's disease, comparing it to a control group of 18 patients receiving conventional treatment.
What They Found
The provided abstract did not include specific numerical results regarding the efficacy of alternobaric oxygen therapy on hearing thresholds or vertigo episodes. Therefore, it is not possible to report the quantitative findings on how ABOT impacted patients' hearing or the frequency of their vertigo attacks.
What This Means for Canadian Patients
Without the study's findings, it is not possible to determine the potential benefits or drawbacks of alternobaric oxygen therapy for Canadian patients with Ménière's disease. Further research with complete results would be necessary to assess if this treatment could offer a viable alternative to current therapies.
Canadian Relevance
This study has no direct Canadian connection as it was not conducted in Canada, nor did it involve Canadian researchers or participants.
Study Limitations
A limitation of this study is its relatively small sample size, which may affect the generalizability of its findings.